CellType vs Isomorphic Labs
Isomorphic Labs holds the stronger position because its AlphaFold-derived models are protected from copying and it has raised $2.6 billion, while CellType relies on an open 27 billion parameter model and has raised just $500K.
CellType
Two-person startup using LLMs to simulate cell biology for drug discovery
Isomorphic Labs
AI drug discovery lab spun out of DeepMind, designing medicines with AlphaFold-descended models
Dimension by dimension
| Dimension | CellType | Isomorphic Labs |
|---|---|---|
| Staying power of the core product | A two person team simulating biology with AI agents on top of an open Google model, with no pharma partnerships mentioned yet. | A DeepMind spinout with milestone deals with Lilly, Novartis, and J&J worth over $3 billion combined. |
| Exposure to AI absorbing the product | Marked likely to be absorbed since the entire approach runs on someone else's open model. | Marked only partly absorbed, since its models descend from AlphaFold work it controls. |
| How easily a giant could copy them | Marked likely, given it is two people wrapping an open 27 billion parameter model. | Marked blocked, since its technology derives from proprietary AlphaFold research that Alphabet controls and rivals cannot replicate. |
| Pressure from rivals | Facing better funded rivals for the same pharma deals, including Isomorphic Labs itself, Chai Discovery, and Insilico Medicine, as of July 2026. | Facing no visible customer loss as of July 2026, though Insilico Medicine is ahead on posting clinical results. |
| Financial footing | Has raised $500K total as of March 2026 with 2 employees. | Raised a $2.1 billion Series B and $2.6 billion total as of May 2026. |
| Overall standing rating | Assessed as protection under test as of July 2026, given its minimal patent protection and unproven pharma partnerships. | Assessed as facing heavier pressure than its funding suggests, as of July 2026, because it has not yet matched Insilico Medicine's clinical progress. |
Questions people ask
- CellType vs Isomorphic Labs, which is better positioned for the AI era?
- Isomorphic Labs is better positioned. It has a blocked-copy rating, $2.6 billion in funding, and pharma deals worth over $3 billion in milestones, while CellType has $500K, two employees, and runs on an open AI model that a larger company could copy.
- Is CellType at risk of being replaced by AI itself?
- Yes, CellType is rated likely to be absorbed by AI since it is built on top of an open Google model rather than proprietary technology. Isomorphic Labs is rated only partly exposed because its models descend from AlphaFold work it controls.
- Can a big tech company copy CellType or Isomorphic Labs?
- CellType is rated likely to be copied since it is a small team layered on an open model. Isomorphic Labs is rated blocked, the strongest protection rating given.
- How much funding do CellType and Isomorphic Labs have?
- CellType has raised $500K as of March 2026. Isomorphic Labs raised a $2.1 billion Series B and has $2.6 billion in total funding as of May 2026.
- Does Isomorphic Labs have any weaknesses compared to rivals?
- Yes, despite its funding and blocked-copy rating, Isomorphic Labs is rated losing its protection because Insilico Medicine has already dosed patients and posted Phase IIa results first. CellType has no clinical progress mentioned at all.
Other comparisons with these companies